InflaRx (IFRX) Income from Continuing Operations (2016 - 2026)
InflaRx (IFRX) posted Income from Continuing Operations of 8029268.7 for Q1 2026, down 119.3% sequentially from 41605634.12 in Q4 2025, and up 38.97% YoY from 5777728.8 in Q1 2025.
InflaRx (IFRX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
InflaRx has reported Income from Continuing Operations for 11 years, with the latest figure at 8029268.7 in Q1 2026.
- Quarterly Income from Continuing Operations rose 38.97% year-over-year to 8029268.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9005266.96 (up 342.47% YoY) and the FY2025 annual result came in at 51875498.84, down 4.05% from the prior year.
- Income from Continuing Operations retreated to 8029268.7 in Q1 2026 per IFRX's latest filing, from 41605634.12 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 46881413.11 in Q4 2024 and troughed at 16013648.14 in Q3 2024.
- A 5-year average of 4344372.3 and a median of 11914757.52 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 350.62% in 2022, then soared 455.21% in 2024.
- Over 5 years, Income from Continuing Operations stood at 14135960.85 in 2022, then rose by 6.63% to 13198115.88 in 2023, then jumped by 455.21% to 46881413.11 in 2024, then retreated by 11.25% to 41605634.12 in 2025, then plunged by 119.3% to 8029268.7 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 8029268.7, 41605634.12, and 10535792.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -7.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.03 Mn |
| Dec 31, 2025 | 41.61 Mn |
| Sep 30, 2025 | -10.54 Mn |
| Jun 30, 2025 | -14.04 Mn |
| Mar 31, 2025 | -13.16 Mn |
| Dec 31, 2024 | 46.88 Mn |
| Sep 30, 2024 | -16.01 Mn |
| Jun 30, 2024 | -15.68 Mn |
| Mar 31, 2024 | -12.58 Mn |
| Dec 31, 2023 | -13.20 Mn |
| Sep 30, 2023 | -10.84 Mn |
| Jun 30, 2023 | -9.55 Mn |
| Mar 31, 2023 | -11.91 Mn |
| Dec 31, 2022 | -14.14 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 5.20 Mn |
| Mar 31, 2022 | -14.24 Mn |
| Dec 31, 2021 | -44,446.67 Bn |
| Sep 30, 2021 | -11.23 Mn |
| Jun 30, 2021 | -19.52 Mn |